Screener
Charles River Laboratories CRL Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Proceeds from long-term debt and revolving credit facility | 1,265,258 | 963,363 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (745,927) | (887,706) |
| Proceeds from exercises of stock options | 1,620 | 1 |
| Purchase of treasury stock | (323,881) | (360,484) |
| Payments of contingent consideration | (11,400) | (21,822) |
| Purchase of remaining equity interests of other redeemable noncontrolling interest | — | (19,140) |
| Other, net | (2,607) | (6,458) |
| Net cash provided by (used in) financing activities | 183,063 | (332,246) |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's share buybacks?
- Charles River Laboratories (CRL) reported share buybacks of $115.6M in Q2 2026.
- How has Charles River Laboratories's share buybacks changed year-over-year?
- Charles River Laboratories's share buybacks increased by 1472.3% year-over-year, from $7.35M to $115.6M.
- What is the long-term trend for Charles River Laboratories's share buybacks?
- Over 4 years (2021 to 2025), Charles River Laboratories's share buybacks has grown at a 72.5% compound annual growth rate (CAGR), from $40.71M to $360.67M.
- What does share buybacks mean?
- Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.
Ask your AI about Charles River Laboratories's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude